Preview

Научно-практическая ревматология

Расширенный поиск

ПРЕПАРАТ ЭТАНЕРЦЕПТВ СОВРЕМЕННОЙ РЕВМАТОЛОГИИ

https://doi.org/10.14412/1995-4484-2010-447

Полный текст:

Список литературы

1. <div><p>Weinblatt M.E., Schiff M.H., Ruderman E.M. et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double- blind, active drug-controlled study. Arthr Rheum 2008;58:1921-30.</p><p>Moreland L.W., Baumgartner S.W.,Schiff M.H. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.</p><p>Moreland L.W., Schiff M.H.,Baumgartner S.W. et al. Etanercept therapy in rheumatoid arthritis. Ann Int Med 1999;130:478-86.</p><p>Kavanaugh A., Klareskog L., van der Heijde D. et al. Improvement in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis 2008;67:1444-7.</p><p>Cohen J.D., Zaltni S., Kaiser M.J. et al. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis. Ann Rheum Dis 2004;63:209-10.</p><p>O'Dell J.R., Petersen K., Leff R. et al. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol 2006;33:213-8.</p><p>Chen H.A., Lin K.C., Chen C.H. et al. The effect of etanercept on anti-cyclic citrullinated antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:35-9.</p><p>Combe B., Codreanu C., Fiocco U. et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis 2006;65:1357-62.</p><p>Van der Heide D., Klareskog L., Rodrigez-Valverde V. et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the tempo study, a doubleblind, randomized trial. Arthr Rheum 2006;54:1063-74.</p><p>Hau M., Kneitz C., Tony H.-P. et al. High resolution ultrasound detects a decrease in pannus vascularisation of small finger joints in patients with rheumatoid arthritis receiving treatment with soluble tumour necrosis factor receptor (etanercept). Ann Rheum Dis 2002;61:55-8.</p><p>Klareskog L., Moreland L.W., Cohen S.B. et al. Safety and efficacy of over 10 years of continuous etanercept therapy in patients with rheumatoid arthritis in North America and Europe. Ann Rheum Dis 2008;67(Suppl. II):175.</p><p>Feltelius N., Fored C.M., Blomqvist P. et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005;64:246-52.</p><p>Roux C.H., Brocq O., Valerio L. et al. Etanercept versus glucocorticosteroids intra-articular (IA) injections in rheumatoid arthritis (RA): a randomized double blind study. Ann Rheum Dis 2008;67(Suppl. II):329-30.</p><p>Genovese M.C., Bathon J.M., Martin R.W. et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two-year radiographic and clinical outcomes. Arthr Rheum 2002;46:1443-50.</p><p>Emery P., Breedveld F.C., Hall S. et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet 2008;Jul 15 (Epub ahead of print).</p><p>Anis A., Zhang W., Emery P. et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology (Oxford) 2009;48:1283-9.</p><p>Lovell D., Giannini E., Reiff A. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. New Engl J Med 2000;342:763-9.</p><p>Hochberg M., Tracy J., Hawkins-Holt M., Flores R. Comparison of efficacy of tumor necrosis factor blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl. II):ii13-ii16.</p><p>Malone D., Ortmeier B. Cost efficacy of etanercept versus infliximab plus methotrexate in the treatment of DMARDresistant rheumatoid arthrirtis. Ann Rheum Dis 2002;61(Suppl. 1):340.</p><p>Haraoui P.B., Keystone E.C., Thorne J.C. The Canadian biologic observational switchover survey: functional status of patients with rheumatoid arthritis after switching from infliximab to etanercept therapy. Ann Rheum Dis 2003;62(Suppl. 1):177-8.</p><p>Singh A., Nab H. A meta-analysis of biological response modifiers in the treatment of rheumatoid arthritis for patients failing one or more disease modifying drugs. Ann Rheum Dis 2003;62(Suppl. 1):185-6.</p><p>Buch M.H., Bingham S.J., Bejanaro V. et al. Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept. Arthr Care Res 2007;57:448-53.</p><p>Buch M.H., Conaghan P.G., Quinn M.A. et al. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin ? Ann Rheum Dis 2004;63:1344-6.</p><p>Kievit W., Adang E.M., Fransen J. et al. The effectiveness and medication costs of three anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008;67:1229-34.</p><p>Kristensen L., Geborek P., Saxne T. et al. Adherence to therapy of etanercept and infliximab during first anti-TNF treatment course in rheumatoid arthritis patients. Ann Rheum Dis 2005;64(Suppl. III):431.</p><p>Davis J.C., van der Heijde D., Braun J. et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthr Rheum 2003;48:3230-6.</p><p>Sieper J., Koenig A.S., Baumgartner S. et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis published online May 21, doi: 10.1136/ard.2008.103192.</p><p>Coates I., Mc Gonagle D., Bennett A. et al. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis 2008;67:729-30.</p><p>Mease P., Goffe B., Metz J. et al. Etanercept in the treatment of psoriatic arthritis and psoriasis. Lancet 2000;356:385-90.</p><p>Driessen R.J., Boezeman J.B., van de Kerkhof P.C. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Brit J Dermat 2009;160:670-5.</p><p>Fautrel B., Sibilia J., Mariette X. et al. Tumour necrosis factor blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005;64:262-6.</p><p>Efthimiou P., Schwartzman S., Kagen L.J. Possible role for tumor necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2005;65:1233-6.</p><p>Fresko J., Mat G. Short-term trial of etanercept in Behcet's disease: a doubleblind, placebo-controlled study. J Rheumatol 2005;32:98-105.</p><p>Moutsopoulos N.M., Katsifis G.E., Angelov N. et al. Lack of efficacy of etanercept in Sjogren's syndrome correlates with failed suppression of tumor necrosis factor and systemic immune activation. Ann Rheum Dis 2008;67:1437-43.</p><p>Fleischmann R., Baumgartner S.W., Weisman M.H. et al. Long-term safety of etanercept in elderly subjects with rheumatoid arthritis. Ann Rheum Dis 2006;65:379-84.</p><p>Singh J.A., Christensen R., Wells G. et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews (Review). Cochrane Database of Systematic Reviews, Issue 4, 2009.</p><p>Bongartz T., Warren F.C., Mines D. et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies. A systematic review and individual patient data metaanalysis of Randomized Controlled Trials. Ann Rheum Dis 2008;Nov 19 (Epub ahead of print).</p><p>Mariette X., Tubach F., Baheri H. et al. Lymphoma in patients treated with anti- TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010;69:400-8.</p><p>Haider A.S., Cardinale J.R., Whynot J.A. et al. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in cultivated human leukocytes. J Invest Derm Symp Proc 2007;12:9-15.</p><p>Tubach F., Salmon D., Ravaud P. et al. The risk of tuberculosis with anti-TNF is higher with monoclonal antibodies than with the soluble receptor. Ann Rheum Dis 2008;67(Suppl. II):52.</p><p>Seong S.-S., Choi C.-B., Woo J.-H. Incidence of TB in Korean patients with RA: Effects of RA itself and of TNF blockers. J Rheumatol 2007;34:706.</p><p>G.E.A.R. Rheumatoid Arthritis study group. Portuguese society for rheumatology. Tuberculosis in patients treated with anti- TNF-alpha therapy. The Portuguese experience. Ann Rheum Dis 2006;65(Suppl. II):498.</p><p>Ruderman E.M., Markenson J.A. Granulomatous infections and tumor necrosis factor antagonists therapy. Ann Rheum Dis 2003;62(Suppl. 1):172-3.</p><p>Thiеfin G., Morelet A., Heurgue' A. et al. Infliximab-induced hepatitis: Absence of cross-toxicity with etanercept. Joint Bone Spine, 2008, Aug 5 (Epub ahead of print).</p><p>Aikawa E.N., de Carvalho J.F., Almeida Silva A.C. et al. Immunogenicity of anti- TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2009;Jun 30 (Epub ahead of print).</p><p>Насонов Е.Л. Применение ингибиторов фактора некроза опухоли при ревматоидном артрите: место этанерцепта. Науч-практич ревматол 2008;5(прил.):1-20.</p></div><br />


Для цитирования:


Сигидин Я.А., Лукина Г.В. ПРЕПАРАТ ЭТАНЕРЦЕПТВ СОВРЕМЕННОЙ РЕВМАТОЛОГИИ. Научно-практическая ревматология. 2010;48(3):78-82. https://doi.org/10.14412/1995-4484-2010-447

For citation:


Sigidin Y.A., Lukina G.V. PREPARAT ETANERTsEPTV SOVREMENNOY REVMATOLOGII. Rheumatology Science and Practice. 2010;48(3):78-82. (In Russ.) https://doi.org/10.14412/1995-4484-2010-447

Просмотров: 519


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)